---
layout: default
title: Prednisone
description: "Prednisone çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 140
evidence_level: L1
indication_count: 10
---

# Prednisone

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Prednisoneï¼šå¾é¢¨æ¿•æ€§ç–¾ç—…åˆ°åœ“ç¦¿ç—‡

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Prednisone å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Prednisone æ˜¯ä¸€ç¨®å»£æ³›ä½¿ç”¨çš„çš®è³ªé¡å›ºé†‡ï¼ŒåŸæœ¬ç”¨æ–¼é¢¨æ¿•æ€§é—œç¯€ç‚ã€æ°£å–˜ã€ä¼‘å…‹ç­‰å¤šç¨®é©æ‡‰ç—‡ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**åœ“ç¦¿ç—‡ (Alopecia Areata)** æœ‰æ•ˆï¼Œç›®å‰æœ‰ **30+ å€‹è‡¨åºŠè©¦é©—**å’Œ **å¤šç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | é¢¨æ¿•æ€§é—œç¯€ç‚ã€æ€¥æ€§ç—…ç—‡ï¼ˆæ°£å–˜ã€ä¼‘å…‹ï¼‰ã€çš®è†šç–¾æ‚£ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | alopecia areataã€alopecia mucinosaã€telogen effluviumã€Quinquaud's folliculitis decalvansã€alopecia antibody deficiencyã€hereditary hypotrichosis with recurrent skin vesiclesã€alopecia-intellectual disability-hypergonadotropic hypogonadism syndromeã€atrichia with papular lesionsã€tenosynovitisã€granulomatous slack skin disease |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.99% |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Go |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. alopecia areata</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Prednisone æ˜¯ä¸€ç¨®åˆæˆçš®è³ªé¡å›ºé†‡ï¼Œå…·æœ‰å¼·æ•ˆçš„æŠ—ç‚å’Œå…ç–«æŠ‘åˆ¶ä½œç”¨ã€‚å®ƒé€éæŠ‘åˆ¶å¤šç¨®ç‚ç—‡ä»‹è³ªå’Œå…ç–«ç´°èƒåŠŸèƒ½ä¾†ç™¼æ®ä½œç”¨ã€‚</p>

<p>åœ“ç¦¿ç—‡æ˜¯ä¸€ç¨®è‡ªé«”å…ç–«ç–¾ç—…ï¼Œç‰¹å¾µæ˜¯å…ç–«ç³»çµ±æ”»æ“Šæ¯›å›Šå°è‡´è„«é«®ã€‚é€™ç¨®ç–¾ç—…çš„ç—…ç†æ©Ÿè½‰æ¶‰åŠ T ç´°èƒä»‹å°çš„è‡ªé«”å…ç–«åæ‡‰ã€‚Prednisone çš„å…ç–«æŠ‘åˆ¶ä½œç”¨å¯ä»¥æŠ‘åˆ¶é€™ç¨®ç•°å¸¸çš„å…ç–«åæ‡‰ï¼Œå¾è€Œæ¸›å°‘å°æ¯›å›Šçš„æ”»æ“Šã€‚</p>

<p>è‡¨åºŠä¸Šï¼Œçš®è³ªé¡å›ºé†‡ï¼ˆåŒ…æ‹¬ prednisoneï¼‰å·²è¢«å»£æ³›ç”¨æ–¼æ²»ç™‚åš´é‡çš„åœ“ç¦¿ç—‡ï¼Œç‰¹åˆ¥æ˜¯èˆ‡ methotrexate ä½µç”¨æ™‚æ•ˆæœæ›´ä½³ã€‚æœ€æ–°çš„éš¨æ©Ÿå°ç…§è©¦é©—è­‰å¯¦äº†é€™ç¨®çµ„åˆç™‚æ³•çš„æœ‰æ•ˆæ€§ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02953821" target="_blank">NCT02953821</a></td><td>PHASE4</td><td>COMPLETED</td><td>172</td><td>A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04925934" target="_blank">NCT04925934</a></td><td>PHASE2</td><td>COMPLETED</td><td>214</td><td>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05162586" target="_blank">NCT05162586</a></td><td>PHASE2</td><td>COMPLETED</td><td>456</td><td>A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06411249" target="_blank">NCT06411249</a></td><td>PHASE4</td><td>RECRUITING</td><td>350</td><td>A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy an...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03843125" target="_blank">NCT03843125</a></td><td>PHASE3</td><td>TERMINATED</td><td>1147</td><td>A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01652261" target="_blank">NCT01652261</a></td><td>PHASE3</td><td>WITHDRAWN</td><td>0</td><td>Very Early FDG-PET/CT-response Adapted Therapy for Advanced Stage Hodgkin Lympho...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03616912" target="_blank">NCT03616912</a></td><td>PHASE3</td><td>TERMINATED</td><td>830</td><td>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07355218" target="_blank">NCT07355218</a></td><td>PHASE3</td><td>NOT_YET_RECRUITING</td><td>202</td><td>A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04058028" target="_blank">NCT04058028</a></td><td>PHASE2</td><td>COMPLETED</td><td>244</td><td>A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Rozibafusp ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01753401" target="_blank">NCT01753401</a></td><td>PHASE4</td><td>COMPLETED</td><td>38</td><td>A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04582136" target="_blank">NCT04582136</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>146</td><td>Efficacy and Safety of Sirolimus in Patients With Active Systemic Lupus Erythema...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02437890" target="_blank">NCT02437890</a></td><td>PHASE2</td><td>COMPLETED</td><td>312</td><td>A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06887517" target="_blank">NCT06887517</a></td><td>N/A</td><td>RECRUITING</td><td>300</td><td>Chinese Rheumatism Biobank(CRB)</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05352919" target="_blank">NCT05352919</a></td><td>PHASE3</td><td>ENROLLING_BY_INVITATION</td><td>864</td><td>A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Eval...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06046534" target="_blank">NCT06046534</a></td><td>N/A</td><td>COMPLETED</td><td>46</td><td>ERYTHRO Retrospective Medical Chart Review Study to Describe the Experience of S...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01283139" target="_blank">NCT01283139</a></td><td>PHASE2</td><td>COMPLETED</td><td>834</td><td>A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimuma...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03616964" target="_blank">NCT03616964</a></td><td>PHASE3</td><td>COMPLETED</td><td>778</td><td>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03161483" target="_blank">NCT03161483</a></td><td>PHASE2</td><td>COMPLETED</td><td>289</td><td>A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EV...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02037191" target="_blank">NCT02037191</a></td><td>PHASE3</td><td>COMPLETED</td><td>90</td><td>RANDOMIZED DOUBLE-BLIND STUDY MULTICENTRIQUE TESTING THE EFFICIENCY OF the METHO...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03517722" target="_blank">NCT03517722</a></td><td>PHASE3</td><td>TERMINATED</td><td>516</td><td>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Stud...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03845517" target="_blank">NCT03845517</a></td><td>PHASE2</td><td>COMPLETED</td><td>350</td><td>A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANG...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01779479" target="_blank">NCT01779479</a></td><td>PHASE2</td><td>COMPLETED</td><td>333</td><td>Randomized, Open-label, Phase II Study Comparing the Efficacy and the Safety of ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02141672" target="_blank">NCT02141672</a></td><td>PHASE2</td><td>COMPLETED</td><td>265</td><td>A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07332481" target="_blank">NCT07332481</a></td><td>PHASE3</td><td>NOT_YET_RECRUITING</td><td>202</td><td>A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01055496" target="_blank">NCT01055496</a></td><td>PHASE1</td><td>COMPLETED</td><td>103</td><td>AN OPEN-LABEL, PHASE 1 STUDY OF R-CVP OR R-GDP IN COMBINATION WITH INOTUZUMAB OZ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03859570" target="_blank">NCT03859570</a></td><td>PHASE4</td><td>WITHDRAWN</td><td>0</td><td>A Multicenter, Double-blind, Placebo-controlled, Randomized Trial of Pentoxifyll...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01511536" target="_blank">NCT01511536</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>38</td><td>A Phase I/II Study of Cabazitaxel Combined With Abiraterone Acetate and Predniso...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02975336" target="_blank">NCT02975336</a></td><td>PHASE2</td><td>TERMINATED</td><td>469</td><td>A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To E...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01254513" target="_blank">NCT01254513</a></td><td>PHASE2</td><td>COMPLETED</td><td>66</td><td>Randomized Phase II Study Evaluating the Feasibility of a Chemotherapy With Doce...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04835441" target="_blank">NCT04835441</a></td><td>PHASE2</td><td>COMPLETED</td><td>76</td><td>A Randomized, Double-blind, Placebo-controlled Study of ALPN-101 in Systemic Lup...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01972217" target="_blank">NCT01972217</a></td><td>PHASE2</td><td>COMPLETED</td><td>158</td><td>A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Co...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03021499" target="_blank">NCT03021499</a></td><td>PHASE3</td><td>COMPLETED</td><td>358</td><td>A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4571041/" target="_blank">4571041</a></td><td>1973</td><td>Article</td><td>Archives of dermatology</td><td>Alopecia areata. Immunologic studies and treatment with prednisone.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1444509/" target="_blank">1444509</a></td><td>1992</td><td>Article</td><td>Archives of dermatology</td><td>Alopecia areata. A review of therapy, efficacy, safety, and mechanism.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38650498/" target="_blank">38650498</a></td><td>2024</td><td>Article</td><td>Italian journal of dermatology</td><td>Real world evidence: patients with alopecia areata in Italy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36884234/" target="_blank">36884234</a></td><td>2023</td><td>Article</td><td>JAMA dermatology</td><td>Efficacy of Methotrexate Alone vs Methotrexate Plus Low-Dose Prednisone in Patie...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26735937/" target="_blank">26735937</a></td><td>2016</td><td>Article</td><td>Dermatology (Basel, Switzerlan</td><td>Efficacy and Safety of Methotrexate Combined with Low- to Moderate-Dose Corticos...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37467740/" target="_blank">37467740</a></td><td>2023</td><td>Article</td><td>Clinical and experimental derm</td><td>Major improvement of very severe alopecia areata in patients treated with the co...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16019495/" target="_blank">16019495</a></td><td>2005</td><td>Article</td><td>Leukemia &amp; lymphoma</td><td>Alopecia areata and multifocal bone involvement in a young adult with Hodgkin&#x27;s ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23962142/" target="_blank">23962142</a></td><td>2013</td><td>Article</td><td>Journal of cutaneous pathology</td><td>Prominent follicular mucinosis with diffuse scalp alopecia resembling alopecia a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/791152/" target="_blank">791152</a></td><td>1976</td><td>Article</td><td>Archives of dermatology</td><td>Prednisone therapy for alopecia areata. A follow-up report.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8996277/" target="_blank">8996277</a></td><td>1997</td><td>Article</td><td>Journal of the American Academ</td><td>Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/13368875/" target="_blank">13368875</a></td><td>1956</td><td>Article</td><td>Medical times</td><td>Alopecia areata, partialis, and totalis; treatment with cortisone, hydrocortison...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9732014/" target="_blank">9732014</a></td><td>1998</td><td>Article</td><td>International journal of derma</td><td>Severe alopecia areata treated with systemic corticosteroids.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25975385/" target="_blank">25975385</a></td><td>2015</td><td>Article</td><td>Journal of cutaneous pathology</td><td>Circumscribed cicatricial alopecia due to localized sarcoidal granulomas and sin...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16268894/" target="_blank">16268894</a></td><td>2005</td><td>Article</td><td>Journal of the European Academ</td><td>Alopecia areata in Down syndrome: a clinical evaluation.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/911178/" target="_blank">911178</a></td><td>1977</td><td>Article</td><td>Archives of dermatology</td><td>Prednisone therapy for alopecia areata.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/596920/" target="_blank">596920</a></td><td>1977</td><td>Article</td><td>Archives of dermatology</td><td>Alopecia areata and regrowth of hair.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23377403/" target="_blank">23377403</a></td><td>2013</td><td>Article</td><td>Journal of drugs in dermatolog</td><td>Bone mineral density in patients with alopecia areata treated with long-term int...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39824987/" target="_blank">39824987</a></td><td>2025</td><td>Article</td><td>Lasers in medical science</td><td>Alopecia areata treated using CO2 fractional laser with different parameters.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12444333/" target="_blank">12444333</a></td><td>2002</td><td>Article</td><td>Dermatology (Basel, Switzerlan</td><td>Acute diffuse and total alopecia of the female scalp. A new subtype of diffuse a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9484415/" target="_blank">9484415</a></td><td>1998</td><td>Article</td><td>Neurology</td><td>Myasthenia gravis and alopecia areata.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. alopecia mucinosa</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ10 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12447614/" target="_blank">12447614</a></td><td>2003</td><td>Article</td><td>Journal of cutaneous medicine </td><td>Alopecia mucinosa: report of a case and review.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15245540/" target="_blank">15245540</a></td><td>2004</td><td>Article</td><td>Clinical and experimental derm</td><td>Acneiform follicular mucinosis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4235314/" target="_blank">4235314</a></td><td>1968</td><td>Article</td><td>Dermatologische Wochenschrift</td><td>[Follicular mucinosis].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23962142/" target="_blank">23962142</a></td><td>2013</td><td>Article</td><td>Journal of cutaneous pathology</td><td>Prominent follicular mucinosis with diffuse scalp alopecia resembling alopecia a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33617128/" target="_blank">33617128</a></td><td>2021</td><td>Article</td><td>Journal of cutaneous pathology</td><td>Eosinophilic folliculitis, eosinophilic dermatosis of hematologic malignancy and...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10434108/" target="_blank">10434108</a></td><td>1999</td><td>Article</td><td>Annales de dermatologie et de </td><td>[CD30 positive pilotropic lymphoma].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22838088/" target="_blank">22838088</a></td><td>2012</td><td>Article</td><td>Cutis</td><td>Reactive benign follicular mucinosis: a report of 2 cases.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4791680/" target="_blank">4791680</a></td><td>1973</td><td>Article</td><td>Przeglad dermatologiczny</td><td>[Case of follicular mucinosis].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/408988/" target="_blank">408988</a></td><td>1977</td><td>Article</td><td>Zeitschrift fur Hautkrankheite</td><td>[Follicular mucinosis with generalized para-amyloidosis as a cutaneous paraneopl...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4226652/" target="_blank">4226652</a></td><td>1967</td><td>Article</td><td>Zeitschrift fur Haut- und Gesc</td><td>[A clinical contribution on idiopathic follicular mucinosis (alopecia mucinosa H...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. telogen effluvium</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12444333/" target="_blank">12444333</a></td><td>2002</td><td>Article</td><td>Dermatology (Basel, Switzerlan</td><td>Acute diffuse and total alopecia of the female scalp. A new subtype of diffuse a...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. Quinquaud&#x27;s folliculitis decalvans</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ2 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7756498/" target="_blank">7756498</a></td><td>1995</td><td>Article</td><td>Clinical infectious diseases :</td><td>Folliculitis decalvans and human T cell lymphotropic virus type I-associated mye...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15024194/" target="_blank">15024194</a></td><td>2004</td><td>Article</td><td>The American Journal of dermat</td><td>Adult onset folliculocentric langerhans cell histiocytosis confined to the scalp...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. alopecia antibody deficiency</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ2 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40546739/" target="_blank">40546739</a></td><td>2025</td><td>Article</td><td>International medical case rep</td><td>Autoimmune Polyglandular Syndrome Type 2 Presentation with Alopecia Universalis,...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10671997/" target="_blank">10671997</a></td><td>1999</td><td>Article</td><td>Clinical and laboratory haemat</td><td>Systemic lupus erythematosus presenting with haemorrhagic manifestation.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. hereditary hypotrichosis with recurrent skin vesicles</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. atrichia with papular lesions</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.95%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. tenosynovitis</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ4 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02429934" target="_blank">NCT02429934</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>28</td><td>Efficacy of Abatacept in Inflammatory Polyarthritis of Systemic Lupus Erythemato...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06037811" target="_blank">NCT06037811</a></td><td>PHASE2</td><td>RECRUITING</td><td>30</td><td>Early Adalimumab Induction for Treatment of Steroid Dependent Immune Checkpoint ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03632187" target="_blank">NCT03632187</a></td><td>PHASE3</td><td>UNKNOWN</td><td>34</td><td>To Demonstrate the Ability of Abatacept in Comparison to Placebo to Obtain a Low...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01169597" target="_blank">NCT01169597</a></td><td>PHASE4</td><td>COMPLETED</td><td>60</td><td>Short Term Study on the Effect of a Fixed Dose of 12.5 mg of Prednisone as Start...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29197854/" target="_blank">29197854</a></td><td>2017</td><td>Article</td><td>BMJ case reports</td><td>Nivolumab-induced polyarthritis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4573028/" target="_blank">4573028</a></td><td>1973</td><td>Article</td><td>JAMA</td><td>Rheumatoid arthritis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31243239/" target="_blank">31243239</a></td><td>2019</td><td>Article</td><td>Internal medicine (Tokyo, Japa</td><td>Tenosynovitis Induced by an Immune Checkpoint Inhibitor: A Case Report and Liter...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4712221/" target="_blank">4712221</a></td><td>1973</td><td>Article</td><td>The British journal of dermato</td><td>Relapsing polychondritis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33135853/" target="_blank">33135853</a></td><td>2022</td><td>Article</td><td>Internal medicine journal</td><td>Musculoskeletal immune-related adverse events with the use of checkpoint inhibit...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29125905/" target="_blank">29125905</a></td><td>2019</td><td>Article</td><td>Arthritis care &amp; research</td><td>Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33404658/" target="_blank">33404658</a></td><td>2021</td><td>Article</td><td>Rheumatology (Oxford, England)</td><td>Imbalanced MMP-3 and MMP-12 serum levels in systemic lupus erythematosus patient...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33294628/" target="_blank">33294628</a></td><td>2020</td><td>Article</td><td>Journal of clinical tuberculos</td><td>Fatal disseminated Mycobacterium haemophilum infection involving the central ner...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19808693/" target="_blank">19808693</a></td><td>2009</td><td>Article</td><td>Rheumatology (Oxford, England)</td><td>Longitudinal examination with shoulder ultrasound of patients with polymyalgia r...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9636949/" target="_blank">9636949</a></td><td>1998</td><td>Article</td><td>Revue du rhumatisme (English e</td><td>Rheumatoid arthritis in Congo-Brazzaville. A study of thirty-six cases.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14719221/" target="_blank">14719221</a></td><td>2003</td><td>Article</td><td>The Journal of rheumatology</td><td>Intractable pain in a rheumatoid wrist.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8221258/" target="_blank">8221258</a></td><td>1993</td><td>Article</td><td>Clinical and experimental alle</td><td>Nodules, eosinophilia, rheumatism, dermatitis and swelling (NERDS): a novel eosi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18050370/" target="_blank">18050370</a></td><td>2008</td><td>Article</td><td>The Journal of rheumatology</td><td>Developing classification criteria for polymyalgia rheumatica: comparison of vie...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19773289/" target="_blank">19773289</a></td><td>2010</td><td>Article</td><td>Annals of the rheumatic diseas</td><td>Ultrasonographic monitoring of response to therapy in polymyalgia rheumatica.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12841025/" target="_blank">12841025</a></td><td>2003</td><td>Article</td><td>The Israel Medical Association</td><td>Protracted Mycobacterium kansasii carpal tunnel syndrome and tenosynovitis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19202958/" target="_blank">19202958</a></td><td>2008</td><td>Article</td><td>Polskie Archiwum Medycyny Wewn</td><td>Dactylitis and bone lesions at the onset of sarcoidosis: a case report.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9663479/" target="_blank">9663479</a></td><td>1998</td><td>Article</td><td>Arthritis and rheumatism</td><td>Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective f...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40018493/" target="_blank">40018493</a></td><td>2025</td><td>Article</td><td>Cureus</td><td>Flexor Tenosynovitis as the Sole Initial Presentation of Anti-synthetase Syndrom...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30201506/" target="_blank">30201506</a></td><td>2018</td><td>Article</td><td>International journal of infec</td><td>Dissemination of localized Mycobacterium malmoense infection in an immunocomprom...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33827439/" target="_blank">33827439</a></td><td>2021</td><td>Article</td><td>BMC infectious diseases</td><td>Chorea as the presenting feature of acute rheumatic fever in childhood; case rep...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. prolapse of lacrimal gland</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.66%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å¤šå¼µè¨±å¯è­‰ | ä¿ç™Œå¯§ç­‰ | éŒ åŠ‘/æ³¨å°„åŠ‘ | é¢¨æ¿•æ€§é—œç¯€ç‚ã€æ€¥æ€§ç—…ç—‡ã€çš®è†šç–¾æ‚£ç­‰ |

## å®‰å…¨æ€§è€ƒé‡

å®‰å…¨æ€§è³‡è¨Šè«‹åƒè€ƒåŸå» ä»¿å–®ã€‚

é•·æœŸä½¿ç”¨çš®è³ªé¡å›ºé†‡çš„å¸¸è¦‹æ³¨æ„äº‹é …ï¼š
- éª¨è³ªç–é¬†é¢¨éšª
- è¡€ç³–å‡é«˜
- å…ç–«æŠ‘åˆ¶å°è‡´æ„ŸæŸ“é¢¨éšªå¢åŠ 
- è…ä¸Šè…ºçš®è³ªåŠŸèƒ½æŠ‘åˆ¶

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**ç”˜è‰** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”˜è‰å»¶é•·çš®è³ªé¡å›ºé†‡ä½œç”¨
- å»ºè­°ï¼šé¿å…é«˜åŠ‘é‡ç”˜è‰


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Latent Tuberculosis** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**Fibrosis** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**Psychotic Disorders** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**ç³–å°¿ç—…** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šé«˜è¡€ç³–ã€‚

**Water-Electrolyte Imbalance** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šç™²ç™‡ç™¼ä½œã€‚

**Water-Electrolyte Imbalance** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šCorticosteroids may cause hypernatremia, hypokalemia, fluid retention, and elevation in blood pressure...

**Peptic Ulcer Perforation** ğŸŸ¡ Moderate
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå‡ºè¡€ã€æ„ŸæŸ“ã€‚

**Cushing Syndrome** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šCorticosteroids mimic the effects of endogenous cortisol and aldosterone...

**Hyperlipidemias** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**ç”²ç‹€è…ºæ©Ÿèƒ½ä½ä¸‹** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**Myocardial Infarction** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**é‡ç—‡è‚Œç„¡åŠ›** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Muscular Diseases** ğŸŸ¡ Moderate
- å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Keratitis, Herpetic** ğŸŸ¡ Moderate
- ä¸å»ºè­°ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**Toxic Optic Neuropathy** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šProlonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma...

**éª¨è³ªç–é¬†ç—‡** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šCorticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss durin...

**æ¶ˆåŒ–æ€§æ½°ç˜** ğŸŸ¡ Moderate
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå‡ºè¡€ã€‚

**Scleroderma, Localized** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šIn patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in reni...

**Strongyloidiasis** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**Thromboembolism** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šè¡€æ “ã€‚

**Infections** ğŸŸ¢ Minor
- ä¸æ‡‰ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚å¯èƒ½å±åŠç”Ÿå‘½ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šGo**

**ç†ç”±ï¼š**
æœ‰é«˜å“è³ªçš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆåŒ…æ‹¬ 2023 å¹´ç™¼è¡¨æ–¼ JAMA Dermatology çš„ç ”ç©¶ï¼‰è­‰å¯¦ prednisone èˆ‡ methotrexate ä½µç”¨å°åš´é‡åœ“ç¦¿æœ‰æ•ˆã€‚é€™å€‹é æ¸¬æœ‰å……åˆ†çš„è‡¨åºŠè­‰æ“šæ”¯æŒã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ ¹æ“šæ‚£è€…å€‹åˆ¥æƒ…æ³è©•ä¼°é¢¨éšªæ•ˆç›Š
- è€ƒæ…®èˆ‡ methotrexate æˆ– JAK æŠ‘åˆ¶åŠ‘ä½µç”¨
- åˆ¶å®šé•·æœŸç›£æ¸¬è¨ˆç•«ï¼ˆéª¨å¯†åº¦ã€è¡€ç³–ç­‰ï¼‰

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Gemcitabine]({{ "/drugs/gemcitabine/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Vonoprazan]({{ "/drugs/vonoprazan/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Isosorbide Dinitrate]({{ "/drugs/isosorbide_dinitrate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Carboplatin]({{ "/drugs/carboplatin/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Regorafenib]({{ "/drugs/regorafenib/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Prednisoneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/prednisone/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_prednisone,
  title = {Prednisoneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/prednisone/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
